Logo - springer
Slogan - springer

Medicine - Oncology & Hematology | Epigenetic Therapy of Cancer - Preclinical Models and Treatment Approaches

Epigenetic Therapy of Cancer

Preclinical Models and Treatment Approaches

Lübbert, Michael, Jones, Peter A. (Eds.)

2014, X, 325 p. 48 illus., 14 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$149.00

(net) price for USA

ISBN 978-3-642-38404-2

digitally watermarked, no DRM

Included Format: PDF and EPUB

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$189.00

(net) price for USA

ISBN 978-3-642-38403-5

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

  • Devotes detailed attention to the translation of basic research and drug development to clinical applications in the treatment of solid tumors as well as hematologic malignancies and hemoglobinopathy
  • Presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production
  • Discusses DNA methylation abnormalities in depth

The growing knowledge about disturbances of epigenetic gene regulation in hematopoietic stem cell disorders such as myeloid leukemias and preleukemias (myelodysplasias) is now being translated into treatment approaches that target the epigenetic defects pharmacologically. Such approaches include reactivation of tumor suppressor genes and other antiproliferative genes by reversal of DNA hypermethylation through azanucleosides, and use of HDAC inhibitors to reverse gene silencing mediated by chimeric, leukemia-specific transcription factors.

This book first presents the latest evidence derived from preclinical models regarding the epigenetic regulation of hematopoietic stem cell differentiation and hemoglobin production. The significance of DNA methylation abnormalities in hematopoietic disorders and of epigenetic disturbances in lung cancer and other solid tumors is then discussed. A major part of the book, however, relates specifically to the translation of basic research and drug development to clinical applications, and in this context both present and future clinical strategies are considered. Individual chapters are devoted to the use of DNA hypomethylating agents and chromatin-modifying agents, and the treatment of hematologic malignancies and solid tumors by means of epigenetic agents is discussed in detail.

Content Level » Professional/practitioner

Keywords » Carcinoma - Chromatin - DNA Methylation - Histone Organisation - Myelodysplasia

Related subjects » Human Genetics - Internal Medicine - Oncology & Hematology

Table of contents 

The fundamental role of epigenetic regulation for normal and disturbed all growth and differentiation.- Mouse models to study DNA methylation in cancer research.- Epigenetic regulation of normal hematopoietic development.- Epigenetic regulation of globin genes and disturbances in hemoglobinopathies.- DNA methylation abnormalities in hematopoietic disorders: biological significance and methodological approaches.- Epigenetic modifications mediated by the AML1/ETO and MLL leukemia fusion proteins.- Epigenetic abnormalities in lung cancer.- Pharmacodynamic Responses to DNA Methyltransferase Inhibition.- Histone Methyltransferases: Opportunities in Cancer Drug Discovery.- Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.- Clinical Implications of Epigenetic Alterations in Lung Cancer.- Epigenetic disturbances in colorectal cancer.- Epigenetic Therapies in Solid Tumours: from preclinical models to clinical trial results.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Oncology.